MiniMed Group, Inc. (MMED)
| Market Cap | 3.03B |
| Revenue (ttm) | 2.99B +21.1% |
| Net Income | -320.00M |
| EPS | -1.14 |
| Shares Out | 280.82M |
| PE Ratio | n/a |
| Forward PE | 35.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 577,965 |
| Open | 11.00 |
| Previous Close | 11.08 |
| Day's Range | 10.65 - 11.24 |
| 52-Week Range | 10.65 - 20.48 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 22.30 (+106.48%) |
| Earnings Date | Jun 3, 2026 |
About MMED
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company’s platform includes Automated Insulin Delivery (AID) systems f... [Read more]
Financial Performance
In fiscal year 2025, MiniMed Group's revenue was $2.72 billion, an increase of 9.96% compared to the previous year's $2.47 billion. Losses were -$213.00 million, 90.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for MMED stock is "Strong Buy." The 12-month stock price target is $22.3, which is an increase of 106.48% from the latest price.
News
MiniMed Aims to Be 'Self-Driving Car' of Diabetes Care
Diabetes equipment provider MiniMed is aiming to be the “self-driving car” of insulin pumps, says its CEO, Que Dallara. Hot off the heels of the company's IPO, Dallara speaks with Caroline Hyde on the...
MiniMed initiated with a Buy at Benchmark
Benchmark last night initiated coverage of MiniMed (MMED) with a Buy rating and $20 price target MiniMed is the only company with an “across-the-board strategy” for diabetes management, offering conti...
MiniMed initiated with a Buy at Benchmark
Benchmark initiated coverage of MiniMed (MMED) with a Buy rating and $20 price target
MiniMed 780G system software licensed by Health Canada
MiniMed (MMED) announced Health Canada has licensed new software for the MiniMed 780G system. Additionally, the system is now compatible with Fiasp and indicated for adults 18 years and older…
MiniMed announces Health Canada License for Simplera Sync™ Sensor, Type 2 Diabetes Indication with MiniMed™ 780G System
BRAMPTON, Ontario, April 28, 2026 (GLOBE NEWSWIRE) -- MiniMed Group, Inc. (MiniMed; Nasdaq: MMED), a global leader in insulin delivery, announced Health Canada has licensed new software for the MiniMe...
MiniMed to announce financial results for its fourth quarter and full fiscal year 2026
NORTHRIDGE, Calif., April 13, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that it will report financial results for its fourth quarter and full...
MiniMed initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of MiniMed (MMED) with a Buy rating and $20 price target
Deutsche starts MiniMed with Buy on attractive entry point
Deutsche Bank initiated coverage of MiniMed (MMED) with a Buy rating and $20 price target The stock’s current valuation provides an attractive entry point, the analyst tells investors in a…
MiniMed initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of MiniMed (MMED) with a Buy rating and $67 price target representing 67% upside potential. The firm believes the shares are giving “little-to-no credit” for MiniMed’s...
MiniMed initiated with an Outperform at William Blair
William Blair initiated coverage of MiniMed (MMED) with an Outperform rating. The firm says MiniMed is a “pure-play” diabetes devices company with a broad product portfolio spanning insulin pumps, con...
MiniMed initiated with an Overweight at Barclays
Barclays initiated coverage of MiniMed (MMED) with an Overweight rating and $26 price target The company has a “strong cadence” of new product launches in the U.S. and globally which…
MiniMed initiated with a Buy at BofA
BofA analyst Travis Steed initiated coverage of MiniMed (MMED) with a Buy rating and $27 price target following its recent split via an IPO from Medtronic (MDT). MiniMed is at…
MiniMed initiated with an Overweight at Wells Fargo
Wells Fargo initiated coverage of MiniMed (MMED) with an Overweight rating and $26 price target The firm says the company offers a “differentiated, full-stack” automated insulin delivery platform with...
MiniMed initiated with a Buy at Citi
Citi initiated coverage of MiniMed (MMED) with a Buy rating and $23 price target The firm says the company has a full pipeline of diabetes products and offers double-digit revenue…
MiniMed initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of MiniMed (MMED) with an Outperform rating and $20 price target Supported by a refreshed product pipeline with better form factor, outcomes, and patient experience, th...
MiniMed initiated with a Buy at BTIG
BTIG analyst Marie Thibault initiated coverage of MiniMed (MMED) with a Buy rating and $25 price target The firm says MiniMed is the diabetes technology industry’s only “full-stack” company, owning…
MiniMed initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Kall Titchmarsh initiated coverage of MiniMed (MMED) with an Overweight rating and $19 price target reflecting a 31% upside from the current price. The firm expects the…
MiniMed initiated with an Outperform at Mizuho
Mizuho initiated coverage of MiniMed (MMED) with an Outperform rating and $21 price target The firm views the diabetes space as attractive, valued at $18B globally and growing in the…
MiniMed Announces FDA Clearance of MiniMed Flex™, the Company's Smallest Insulin Pump Featuring Its First Smartphone-Controlled Design
MiniMed Flex™ is about half the size of the previous generation MiniMed™ 780G system, and features the SmartGuard™ adaptive algorithm to automatically adjust and autocorrect insulin delivery in real-t...
MiniMed announces closing of Initial Public Offering
NORTHRIDGE, Calif., March 9, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed; Nasdaq: MMED) today announced the closing of its previously announced initial public offering (IPO) of 28,000,000 shares...
Medtronic's diabetes unit MiniMed valued at $5.3 billion as shares fall in Nasdaq debut
Shares of MiniMed , the diabetes business of medical device maker Medtronic , opened 4.8% below their offer price in their Nasdaq debut on Friday, valuing it at $5.3 billion.
MiniMed to begin trading on Nasdaq Global Select Market
GALWAY, Ireland, March 6, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that MiniMed Group, Inc. (Nasdaq: MMED) will begin trading today on the Na...
MiniMed begins trading on Nasdaq Global Select Market
NORTHRIDGE, Calif., March 6, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed; Nasdaq: MMED), a global leader in diabetes management, will begin trading on the Nasdaq Global Select Market (Nasdaq) to...
Medtronic's diabetes unit MiniMed raises $560 million in US IPO
MiniMed, the diabetes business of medical device maker Medtronic , said on Thursday it has raised $560 million in its U.S. initial public offering.
Medtronic's MiniMed aims to raise $784 million in US IPO
Medtronic's diabetes business MiniMed Group said on Tuesday it was aiming to raise as much as $784 million in its initial public offering in the United States.